Immunological aspects of cancer chemotherapy

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · see citing works

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399 · see citing works

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · see citing works

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 1× · see citing works

IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity

Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · see citing works

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823 · see citing works

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works

A cytokine-mediated link between innate immunity, inflammation, and cancer

Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940 · see citing works

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., K.Wansley, E., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052494 · Cited by 1,737 · see citing works

Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma

Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U. S., White, D. E., Mavroukakis, S. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.240 · Cited by 1,625 · see citing works

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512 · see citing works

Induction of Tumor Immunity by Removing CD25+CD4+ T Cells: A Common Basis Between Tumor Immunity and Autoimmunity

Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491 · see citing works

Cell-Surface Calreticulin Initiates Clearance of Viable or Apoptotic Cells through trans-Activation of LRP on the Phagocyte

Gardai, S. J., McPhillips, K. A., Frasch, S. C., Janssen, W. J., Starefeldt, A., Murphy-Ullrich, J. E., Bratton, D. L., Oldenborg, P.-A., Michalak, M., & Henson, P. M. (2005) · Cell · doi:10.1016/j.cell.2005.08.032 · Cited by 1,473 · see citing works

Cancer despite immunosurveillance: immunoselection and immunosubversion

Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324 · see citing works

The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor

Gasser, S., Orsulic, S., Brown, E. J., & Raulet, D. H. (2005) · Nature · doi:10.1038/nature03884 · Cited by 1,308 · see citing works

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

Ghiringhelli, F., Menard, C., Puig, P. E., Ladoire, S., Roux, S., Martin, F., Solary, É., Cesne, A. L., Zitvogel, L., & Chauffert, B. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0225-8 · Cited by 1,241 · see citing works

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells

Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,063 · see citing works

Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo

Fernandez, N. C., Lozier, A., Flament, C., Ricciardi‐Castagnoli, P., Bellet, D. H., Suter, M., Perricaudet, M., Tursz, T., Maraskovsky, E., & Zitvogel, L. (1999) · Nature Medicine · doi:10.1038/7403 · Cited by 1,057 · see citing works

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054 · see citing works

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008 · see citing works

Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor

Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., & Lord, E. M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7516 · Cited by 966 · see citing works

CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner

Ghiringhelli, F., Menard, C., Terme, M., Flament, C., Taı̈eb, J., Chaput, N., Puig, P. E., Novault, S., Escudier, B. J., Vivier, É., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051511 · Cited by 948 · see citing works

Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide

Lutsiak, M. E. C., Semnani, R. T., De Pascalis, R., Kashmiri, S. V. S., Schlom, J., & Sabzevari, H. (2005) · Blood · doi:10.1182/blood-2004-06-2410 · Cited by 903 · see citing works

CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, É., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 878 · see citing works

Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis

Weinblatt, M. E., Coblyn, J. S., Fox, D. A., Fraser, P. A., Holdsworth, D. E., Glass, D. N., & Trentham, D. E. (1985) · New England Journal of Medicine · doi:10.1056/nejm198503283121303 · Cited by 872 · see citing works

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death

Kroemer, G., El-Deiry, W. S., Golstein, P., Peter, M. E., Vaux, D., Vandenabeele, P., Zhivotovsky, B., Blagosklonny, M. V., Malorni, W., Knight, R. A., et al. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401724 · Cited by 843 · see citing works

Cancer--A Biological Approach: I. The Processes Of Control. II. The Significance of Somatic Mutation

Burnet, M. (1957) · BMJ · doi:10.1136/bmj.1.5022.779 · Cited by 811 · see citing works

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

North, R. J. (1982) · The Journal of Experimental Medicine · doi:10.1084/jem.155.4.1063 · Cited by 650 · see citing works

Immunotherapy and chemotherapy — a practical partnership

Lake, R., & Robinson, B. W. S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1613 · Cited by 649 · see citing works

Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells

Galon, J., Franchimont, D., Hiroi, N., Frey, G., Boettner, A., Ehrhart-Bornstein, M., O’shea, J. J., Chrousos, G. P., & Bornstein, S. R. (2002) · The FASEB Journal · doi:10.1096/fj.01-0245com · Cited by 606 · see citing works

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling

Paulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586 · see citing works

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

Apétoh, L., Ghiringhelli, F., Tesnière, A., Criollo, A., Ortiz, C., Lidereau, R., Mariette, C., Chaput, N., Mira, J. P., Delaloge, S., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00573.x · Cited by 575 · see citing works

Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes

Garnett‐Benson, C., Palena, C., Chakarborty, M., Tsang, K.-Y., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1525 · Cited by 557 · see citing works

Decreased tumor surveillance in perforin-deficient mice.

van den Broek, M. F., Kägi, D., OSSENDORP, F. A., Toes, R. E. M., Vamvakas, S. M., Lutz, W. K., Melief, C. J. M., Zinkernagel, R. M., & Hengartner, H. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.5.1781 · Cited by 513 · see citing works

Homeostasis-Stimulated Proliferation Drives Naive T Cells to Differentiate Directly into Memory T Cells

Cho, B. K., Rao, V. P., Ge, Q., Eisen, H. N., & Chen, J. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.549 · Cited by 509 · see citing works

Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis

Obeid, M., Panaretakis, T., Joza, N., Tufi, R., Tesniere, A., van Endert, P., Zitvogel, L., & Kroemer, G. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402201 · Cited by 474 · see citing works

Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial

Panici, P. B., Maggioni, A., Hacker, N. F., Landoni, F., Ackermann, S., Campagnutta, E., Tamussino, K. F., Winter, R., Pellegrino, A., Greggi, S., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji102 · Cited by 465 · see citing works

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., & Robinson, B. W. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4905 · Cited by 463 · see citing works

Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.

Machiels, J.-P., Reilly, R. T., Emens, L. A., Ercolini, A. M., Lei, R. Y., Weintraub, D., Okoye, F. I., & Jaffee, E. M. (2001) · PubMed · Cited by 455 · see citing works

Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2013 · Cited by 444 · see citing works

B cells inhibit induction of T cell-dependent tumor immunity

Qin, Z.-H., Richter, G., Schüler, T., Ibe, S., Cao, X.-T., & Blankenstein, T. (1998) · Nature Medicine · doi:10.1038/nm0598-627 · Cited by 440 · see citing works

External Beam Radiation of Tumors Alters Phenotype of Tumor Cells to Render Them Susceptible to Vaccine-Mediated T-Cell Killing

Chakraborty, M., Abrams, S. I., Coleman, C. N., Camphausen, K. A., Schlom, J., & Hodge, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0073 · Cited by 435 · see citing works

Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.

Nowak, A. K., Robinson, B. W. S., & Lake, R. (2003) · PubMed · Cited by 414 · see citing works

A novel dendritic cell subset involved in tumor immunosurveillance

Taı̈eb, J., Chaput, N., Menard, C., Apétoh, L., Ullrich, E., Bonmort, M., Péquignot, M. O., Casares, N., Terme, M., Flament, C., et al. (2006) · Nature Medicine · doi:10.1038/nm1356 · Cited by 403 · see citing works

Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination

Badovinac, V. P., Messingham, K. N., Jabbari, A., Haring, J. S., & Harty, J. T. (2005) · Nature Medicine · doi:10.1038/nm1257 · Cited by 403 · see citing works

Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications

Spisek, R., Charalambous, A., Mazumder, A., Vesole, D. H., Jagannath, S., & Dhodapkar, M. V. (2007) · Blood · doi:10.1182/blood-2006-10-054221 · Cited by 388 · see citing works

Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?

Muranski, P. J., Boni, A., Wrzesinski, C., Citrin, D. E., Rosenberg, S. A., Childs, R. W., & Restifo, N. P. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0666 · Cited by 358 · see citing works

“Of mice and men”

Kelland, L. R. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2003.11.028 · Cited by 352 · see citing works

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

Borg, C., Terme, M., Taïeb, J., Ménard, C., Flament, C., Robert, C., Maruyama, K., Wakasugi, H., Angevin, E., Thielemans, K., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21102 · Cited by 302 · see citing works

Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells

Binder, R. J., & Srivastava, P. K. (2005) · Nature Immunology · doi:10.1038/ni1201 · Cited by 295 · see citing works

Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner

Seggewiss, R. (2004) · Blood · doi:10.1182/blood-2004-07-2527 · Cited by 291 · see citing works

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.

Arlen, P. M., Gulley, J. L., Parker, C., Skarupa, L., Pazdur, M. P., Panicali, D., Beetham, P. K., Tsang, K. Y., Grosenbach, D. W., Feldman, J. L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2059 · Cited by 287 · see citing works

Primary Tumor Tissue Lysates Are Enriched in Heat Shock Proteins and Induce the Maturation of Human Dendritic Cells

Somersan, S., Larsson, M., Fonteneau, J., Basu, S., Srivastava, P. K., & Bhardwaj, N. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.4844 · Cited by 259 · see citing works

Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide.

Berd, D., Maguire, H. C., Jr., & Mastrangelo, M. J. (1986) · PubMed · Cited by 251 · see citing works

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2?-deoxycytidine treatment

Serrano, A., Tanzarella, S., Lionello, I., Méndez, R., Traversari, C., Ruiz‐Cabello, F., & Garrido, F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1452 · Cited by 239 · see citing works

Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.

Nowak, A. K., Robinson, B. W. S., & Lake, R. (2002) · PubMed · Cited by 238 · see citing works

Effect of Cyclophosphamide on Immunological Control Mechanisms

Turk, J. L., & Parker, D. (1982) · Immunological Reviews · doi:10.1111/j.1600-065x.1982.tb00429.x · Cited by 237 · see citing works

Antibodies, Fc receptors and cancer

Nimmerjahn, F., & Ravetch, J. V. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.01.005 · Cited by 235 · see citing works

Food groups and risk of oral and pharyngeal cancer

Levi, F., Pasche, C., Vecchia, C. L., Lucchini, F., Franceschi, S., & Monnier, P. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980831)77:5 · Cited by 228 · see citing works

Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

Atzpodien, J., Kirchner, H. H., Udo Jonas, A., Bergmann, L., Schott, H., Heynemann, H., Fornara, P., Loening, S. A., Roigas, J., Müller, S. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.155 · Cited by 223 · see citing works

Ecto‐calreticulin in immunogenic chemotherapy

Obeid, M., Tesniere, A., Panaretakis, T., Tufi, R., Joza, N., Van Endert, P., Ghiringhelli, F., Apetoh, L., Chaput, N., Flament, C., et al. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00567.x · Cited by 202 · see citing works

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells

Wrzesinski, C., Paulos, C. M., Gattinoni, L., Palmer, D. C., Kaiser, A., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30414 · Cited by 202 · see citing works

Cyclophosphamide induces type I interferon and augments the number of CD44hi T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer

Schiavoni, G., Mattei, F., Pucchio, T. D., Santini, S. M., Bracci, L., Belardelli, F., & Proietti, E. (2000) · Blood · doi:10.1182/blood.v95.6.2024 · Cited by 196 · see citing works

Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma

Lech‐Marańda, E. (2004) · Blood · doi:10.1182/blood-2003-06-1850 · Cited by 187 · see citing works

Antivascular therapy of cancer: DMXAA

Baguley, B. C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01018-0 · Cited by 187 · see citing works

Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas

PLATE, J. M. D., Plate, A. E., Shott, S., Bograd, S., & Harris, J. E. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0638-1 · Cited by 176 · see citing works

Antigen Concentration and Precursor Frequency Determine the Rate of CD8+ T Cell Tolerance to Peripherally Expressed Antigens

Morgan, D. J. W., Kreuwel, H. T. C., & Sherman, L. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.723 · Cited by 171 · see citing works

Chemo-Immunotherapy of Metastatic Colorectal Carcinoma With Gemcitabine Plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer Patients

Correale, P., Cusi, M. G., Tsang, K. Y., Vecchio, M. T. D., Marsili, S., Placa, M. L., Intrivici, C., Aquino, A., Micheli, L., Nencini, C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.12.147 · Cited by 171 · see citing works

The chemotherapeutic agent DMXAA potently and specifically activates the TBK1–IRF-3 signaling axis

Roberts, Z. J., Goutagny, N., Perera, P., Kato, H., Kumar, H., Kawai, T., Akira, S., Savan, R., Echo, D. V., Fitzgerald, K. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061845 · Cited by 167 · see citing works

Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.

Berd, D., & Mastrangelo, M. J. (1988) · PubMed · Cited by 167 · see citing works

DNA Methylation Inhibitors in the Treatment of Leukemias, Myelodysplastic Syndromes and Hemoglobinopathies: Clinical Results and Possible Mechanisms of Action

Lübbert, M. (2000) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-59696-4_9 · Cited by 167 · see citing works

Tumor Antigens are Constitutively Presented in the Draining Lymph Nodes

Marzo, A. L., Lake, R., Lo, D. D., Sherman, L. A., McWilliam, A., Nelson, D. J., Robinson, B. W. S., & Scott, B. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.10.5838 · Cited by 166 · see citing works

Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy

Gribben, J. G., Ryan, D. P., Boyajian, R. N., Urban, R. G., Hedley, M. L., Beach, K. J., Nealon, P., Matulonis, U. A., Campos, S. M., Gilligan, T. D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2111 · Cited by 165 · see citing works

Dacarbazine, Cisplatin, and Interferon-Alfa-2b With or Without Interleukin-2 in Metastatic Melanoma: A Randomized Phase III Trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group

Keilholz, U., Punt, C. J. A., Gore, M. E., Kruit, W. H. J., Patel, P., Líénard, D., Thomas, J., Proebstle, T. M., Schmittel, A. H., Schadendorf, D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.202 · Cited by 165 · see citing works

Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors

Rožková, D., Horváth, R., Bartůňková, J., & Špíšek, R. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.04.567 · Cited by 164 · see citing works

Late and persistent up-regulation of intercellular adhesion molecule-1 (ICAM-1) expression by ionizing radiation in human endothelial cells in vitro

Gaugler, M. (1997) · International Journal of Radiation Biology · doi:10.1080/095530097143428 · Cited by 164 · see citing works

Enhancing the Effect of THERATOPE STn-KLH Cancer Vaccine in Patients with Metastatic Breast Cancer by Pretreatment with Low-Dose Intravenous Cyclophosphamide

MacLean, G. D., Miles, D. W., Rubens, R. D., Reddish, M. A., & Longenecker, B. M. (1996) · Journal of Immunotherapy · doi:10.1097/00002371-199607000-00006 · Cited by 161 · see citing works

CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation

Milas, L., Mason, K. A., Ariga, H., Hunter, N. R., Neal, R. E., Valdecanas, D. R., Krieg, A. Μ., & Whisnant, J. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0926 · Cited by 151 · see citing works

Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects

Weiner, H. L., & Cohen, J. A. (2002) · Multiple Sclerosis Journal · doi:10.1191/1352458502ms790oa · Cited by 148 · see citing works

The immunological effects of taxanes

Chan, O. T. M., & Yang, L. (2000) · Cancer Immunology Immunotherapy · doi:10.1007/s002620000122 · Cited by 148 · see citing works

Activation of Tumor-Associated Macrophages by the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid Induces an Effective CD8+ T-Cell–Mediated Antitumor Immune Response in Murine Models of Lung Cancer and Mesothelioma

Jassar, A. S., Suzuki, E., Kapoor, V., Sun, J., Silverberg, M. B., Cheung, L., Burdick, M. D., Strieter, R. M., Ching, L., Kaiser, L. R., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1658 · Cited by 145 · see citing works

Immune Response Against Dying Tumor Cells

Zitvogel, L., Casares, N., Péquignot, M. O., Chaput, N., Albert, M. L., & Kroemer, G. (2004) · Advances in immunology · doi:10.1016/s0065-2776(04)84004-5 · Cited by 129 · see citing works

One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases

Grünhagen, D. J., Brunstein, F., Graveland, W. J., van Geel, A. N., de Wilt, J. H. W., & Eggermont, A. M. M. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000146147.89667.ed · Cited by 126 · see citing works

FASL –844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer

Sun, T., Zhou, Y., Li, H., Han, X., Shi, Y., Wang, L., Miao, X., Tan, W., Zhao, D., Zhang, X., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050707 · Cited by 125 · see citing works

Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments

Ge, Q., Hu, H., Eisen, H. N., & Chen, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052714099 · Cited by 121 · see citing works

Regulation of specific cell-mediated cytotoxic response against SV40-induced tumor associated antigens by depletion of suppressor T cells with cyclophosphamide in mice.

Glaser, M. (1979) · The Journal of Experimental Medicine · doi:10.1084/jem.149.3.774 · Cited by 119 · see citing works

Paclitaxel Enhances Macrophage IL-12 Production in Tumor-Bearing Hosts Through Nitric Oxide

Mullins, D. W., Burger, C. J., & Elgert, K. D. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.11.6811 · Cited by 116 · see citing works

Inhibitory Effect of Toll-Like Receptor 4 on Fusion between Phagosomes and Endosomes/Lysosomes in Macrophages

Shiratsuchi, A., Watanabe, I., Takeuchi, O., Akira, S., & Nakanishi, Y. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2039 · Cited by 112 · see citing works

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma

Bajetta, E., Vecchio, M. D., Nova, P., Fusi, A., Daponte, A., Sertoli, M. R., Queirolo, P., Taveggia, P., Bernengo, M. G., Legha, S. S., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl007 · Cited by 112 · see citing works

Increased frequency ofATM mutations in breast carcinoma patients with early onset disease and positive family history

Teraoka, S. N., Malone, K. E., Doody, D. R., Suter, N. M., Ostrander, E. A., Daling, J. R., & CONCANNON, P. J. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3 · Cited by 111 · see citing works

Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer.

Yu, B., Kusmartsev, S. A., Cheng, F., Paolini, M., Nefedova, Y., Sotomayor, E. M., & Gabrilovich, D. I. (2003) · PubMed · Cited by 104 · see citing works

Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan.

Thom, A. K., Alexander, H. R., Andrich, M. P., Barker, W. C., Rosenberg, S. A., & Fraker, D. L. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.264 · Cited by 103 · see citing works

Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia

Li, Z., Qiao, Y., Liu, B., Laska, E. J., Chakravarthi, P., Kulko, J. M., Bona, R., Fang, M., Hegde, U. P., Moyo, V. M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0250 · Cited by 102 · see citing works

Cancer Immunologists and Cancer Biologists: Why We Didn't Talk Then but Need to Now

Prendergast, G. C., & Jaffee, E. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4626 · Cited by 101 · see citing works

Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.

Mattiuzzi, G. N., Cortes, J. E., Talpaz, M., Reuben, J. M., Rios, M. B., Shan, J., Kontoyiannis, D. P., Giles, F. J., RAAD, I. I., Verstovšek, S., et al. (2003) · PubMed · Cited by 101 · see citing works

Immunotherapy for human cancer using heat shock protein-peptide complexes

Srivastava, P. K. (2005) · Current Oncology Reports · doi:10.1007/s11912-005-0035-8 · Cited by 98 · see citing works

Cellular Immunity in Breast Cancer Patients Completing Taxane Treatment

Carson, W. E., Shapiro, C. L., Crespin, T. R., Thornton, L. M., & Andersen, B. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1016-03 · Cited by 94 · see citing works

Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice.

Orsini, F. R., Pavelić, Z. P., & Mihich, E. (1977) · PubMed · Cited by 85 · see citing works

Molecular analysis of the methylprednisolone-mediated inhibition of NK-cell function: evidence for different susceptibility of IL-2– versus IL-15–activated NK cells

Chiossone, L., Vitale, C., Cottalasso, F., Moretti, S., Azzarone, B. G., Moretta, L., & Mingari, M. C. (2007) · Blood · doi:10.1182/blood-2006-07-037846 · Cited by 81 · see citing works

Polymorphisms of interleukin (IL)-1α, IL-1β, IL-6, IL-10, and IL-18 and the risk of ovarian cancer

Bushley, A. W., Ferrell, R. E., McDuffie, K., Terada, K. Y., Carney, M. E., Thompson, P. J., Wilkens, L. R., Tung, K., Ness, R. B., & Goodman, M. T. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.08.024 · Cited by 76 · see citing works

Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells

Galetto, A., Buttiglieri, S., Forno, S., Moro, F., Mussa, A., & Matera, L. (2003) · Anti-Cancer Drugs · doi:10.1097/00001813-200311000-00010 · Cited by 73 · see citing works

Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections

Mumprecht, S., Matter, M. S., Pavelic, V., & Ochsenbein, A. F. (2006) · Blood · doi:10.1182/blood-2006-04-018705 · Cited by 70 · see citing works

Efficacy of GM-CSF-producing Tumor Vaccine after Docetaxel Chemotherapy in Mice Bearing Established Lewis Lung Carcinoma

Chu, Y., Wang, L.-X., Yang, G., Ross, H. J., Urba, W. J., Prell, R. A., Jooss, K. U., Xiong, S., & Hu, H. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000199198.43587.ba · Cited by 67 · see citing works

Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor‐specific antitumor effect in vivo

Tanaka, F., Yamaguchi, H., Ohta, M., Mashino, K., Sonoda, H., Sadanaga, N., Inoue, H., & Mori, M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10597 · Cited by 65 · see citing works

Lymphopenia: A new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma

Claude, L., Pérol, D., Ray-Coquard, I. L., Petit, T., Blay, J., Carrié, C., & Bachelot, T. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.06.004 · Cited by 61 · see citing works

Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patients

Noguchi, M., Itoh, K., Yao, A., Mine, T., Yamada, A., Obata, Y., Furuta, M., Harada, M., Suekane, S., & Matsuoka, K. (2004) · The Prostate · doi:10.1002/pros.20157 · Cited by 58 · see citing works

Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines.

Nigam, A., Yacavone, R. F., ZAHURAK, M. L., Johns, C. M., Pardoll, D. M., Piantadosi, S., Levitsky, H. I., & Nelson, W. G. (1998) · International Journal of Oncology · doi:10.3892/ijo.12.1.161 · Cited by 58 · see citing works

Immunomodulation of Natural Killer Cell Activity by Flavone Acetic Acid: Occurrence Via Induction of Interferon /beta

Hornung, R. L., Young, H. A., Urba, W. J., & Wiltrout, R. H. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.15.1226 · Cited by 56 · see citing works

Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice.

Kozar, K., Kamiński, R., Świtaj, T., Ołdak, T., Machaj, E. K., Wysocki, P. J., Mackiewicz, A. A., Lasek, W., Jakóbisiak, M., & Gołąb, J. (2003) · PubMed · Cited by 45 · see citing works

Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients.

Arinaga, S., Akiyoshi, T., & Tsuji, H. (1986) · PubMed · Cited by 44 · see citing works

5-Fluorouracil–Based Chemotherapy Enhances the Antitumor Activity of a Thymidylate Synthase–Directed Polyepitopic Peptide Vaccine

Correale, P., Vecchio, M. T. D., Genova, G. D., Savellini, G. G., Placa, M. L., Terrosi, C., Vestri, M., Urso, R., Lemonnier, F. A., Aquino, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji188 · Cited by 43 · see citing works

Interleukin-2/interferon-α2a/13-retinoic acid-based chemoimmunotherapy in advanced renal cell carcinoma: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

D. –. G. C. R. C. C. T. G., Atzpodien, J., Kirchner, H. H., Rebmann, U., Soder, M., Gertenbach, U., Siebels, M., Roigas, J., Raschke, R., Salm, S., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603271 · Cited by 42 · see citing works

Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer

Gomez, G. G., Hutchison, R., & Kruse, C. A. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2001.0222 · Cited by 35 · see citing works

Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms

Levitt, M. L., Kassem, B. E. B., Gooding, W. E., Miketic, L. M., Landreneau, R. J., Ferson, P. F., Keenan, R., Yousem, S. A., Lindberg, C., Trenn, M. R., et al. (2003) · Lung Cancer · doi:10.1016/j.lungcan.2003.09.011 · Cited by 31 · see citing works

Intrapleural cisplatin and OK432 therapy for malignant pleural effusion caused by non‐small cell lung cancer

Ishida, A., Miyazawa, T., Miyazu, Y., Iwamoto, Y., Zaima, M., Kanoh, K., Sumiyoshi, H., & Masao, D. O. I. (2006) · Respirology · doi:10.1111/j.1440-1843.2006.00790.x · Cited by 30 · see citing works

Influence of longterm therapy with methotrexate and low dose corticosteroids on type 1 and type 2 cytokine production in CD4+ and CD8+ T lymphocytes of patients with rheumatoid arthritis.

Schuerwegh, A. J., Offel, J. F. V., Bridts, C. H., Stevens, W. J., & Clerck, L. S. D. (2001) · PubMed · Cited by 23 · see citing works

Effect of radiation on the expression of carcinoembryonic antigen on the membranes of human gastric adenocarcinoma cells--immunological study using monoclonal antibodies.

Hareyama, M., Imai, K., Ban, T., Koshiba, H., Kubo, K., Shidou, M., Oouchi, A., & Morita, K. (1988) · PubMed · Cited by 8 · see citing works

Phase I Study of Low-Dose Interleukin-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia

Kasamon, Y. L., Flinn, I. W., Grever, M. R., Diehl, L. F., Garrett-Mayer, E. S., Goodman, S. N., Lucas, M. S., & Byrd, J. C. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1612 · Cited by 7 · see citing works

Short Communication: The Efficacy of Fixed Dose Rate Infusion of Gemcitabine Combined with IFN-α2a in Patients with Advanced Refractory Renal Cell Carcinoma

Massacesi, C., Burattini, L., Marcucci, F., & Bonsignori, M. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.165 · Cited by 6 · see citing works

Restoration of macrophage tumoricidal activity by bleomycin correlates with the decreased production of transforming growth factor ? in rats bearing KDH-8 hepatoma cells

Yuan, L., Kobayashi, M., Kuramitsu, Y., Li, Y., Matsushita, K., & Hosokawa, M. (1997) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050404 · Cited by 6 · see citing works

Untitled work

(2001) · doi:10.1002/1521-4141(200108)31:8

Immunity, Inflammation, and Cancer

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · see citing works

The immune contexture in human tumours: impact on clinical outcome

Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · see citing works

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · see citing works

Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments

Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,023 · see citing works

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · see citing works

Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009

Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399 · see citing works

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079 · see citing works

NF-κB, inflammation, immunity and cancer: coming of age

Taniguchi, K., & Karin, M. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.142 · Cited by 2,679 · see citing works

Influence of tumour micro-environment heterogeneity on therapeutic response

Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694 · see citing works

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,389 · see citing works

Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898 · see citing works

Nanotechnology for Multimodal Synergistic Cancer Therapy

Fan, W., Yung, B. C., Huang, P., & Chen, X. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,804 · see citing works

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

Denkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb‐Esfahani, S., Kronenwett, R., Hanusch, C. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,751 · see citing works

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade

Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648 · see citing works

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662 · see citing works

Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance

Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,617 · see citing works

Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation

Solinas, G., Germano, G., Mantovani, A., & Allavena, P. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0609385 · Cited by 1,418 · see citing works

Translational biology of osteosarcoma

Kansara, M., Teng, M. W., Smyth, M. J., & Thomas, D. M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3838 · Cited by 1,294 · see citing works

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell–Dependent Antitumor Immunity

Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M., Chevriaux, A., Martin, F., Apetoh, L., Rébé, C., & Ghiringhelli, F. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3690 · Cited by 1,245 · see citing works

Immunogenic and tolerogenic cell death

Green, D. R., Ferguson, T., Zitvogel, L., & Kroemer, G. (2009) · Nature Reviews Immunology · doi:10.1038/nri2545 · Cited by 1,176 · see citing works

Nanoparticles for Cancer Therapy: Current Progress and Challenges

Gavas, S., Quazi, S., & Karpiński, T. M. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03628-6 · Cited by 1,069 · see citing works

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

Lynch, T. J., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Neal, J. W., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 999 · see citing works

Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

Li, K., Shi, H., Zhang, B., Ou, X., Ma, Q., Chen, Y., Shu, P., Li, D., & Wang, Y.-S. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00670-9 · Cited by 914 · see citing works

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P. K., Smyth, M. J., & Loi, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.215 · Cited by 890 · see citing works

Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients

Ooft, S. N., Weeber, F., Dijkstra, K. K., McLean, C. M., Kaing, S., van Werkhoven, E., Schipper, L., Hoes, L., Vis, D. J., van de Haar, J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aay2574 · Cited by 813 · see citing works

Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance

Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 879 · see citing works

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial

Nywening, T. M., Wang‐Gillam, A., Sanford, D. E., Belt, B. A., Panni, R. Z., Cusworth, B. M., Toriola, A. T., Nieman, R., Worley, L. A., Yano, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00078-4 · Cited by 818 · see citing works

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Kang, Y., Chen, L., Ryu, M., Oh, D., Oh, S. C., Chung, H. C., Lee, K., Omori, T., Shitara, K., Sakuramoto, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00692-6 · Cited by 810 · see citing works

Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth

Bruchard, M., Mignot, G., Dérangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2999 · Cited by 775 · see citing works

Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy

He, C., Duan, X., Guo, N., Chan, C., Poon, C. J., Weichselbaum, R. R., & Lin, W. (2016) · Nature Communications · doi:10.1038/ncomms12499 · Cited by 755 · see citing works

Turning the corner on therapeutic cancer vaccines

Hollingsworth, R. E., & Jansen, K. (2019) · npj Vaccines · doi:10.1038/s41541-019-0103-y · Cited by 689 · see citing works

Origins of tumor-associated macrophages and neutrophils

Cortez‐Retamozo, V., Etzrodt, M., Newton, A., Rauch, P. J., Chudnovskiy, A., Berger, C., Ryan, R. J. H., Iwamoto, Y., Marinelli, B. S., Gorbatov, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113744109 · Cited by 680 · see citing works

Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges

Day, C.-P., Merlino, G., & Van Dyke, T. (2015) · Cell · doi:10.1016/j.cell.2015.08.068 · Cited by 676 · see citing works

The secret ally: immunostimulation by anticancer drugs

Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670 · see citing works

Immune parameters affecting the efficacy of chemotherapeutic regimens

Zitvogel, L., Kepp, O., & Kroemer, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.223 · Cited by 665 · see citing works

Metronomic chemotherapy: new rationale for new directions

Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 655 · see citing works

Cytokines and their relationship to the symptoms and outcome of cancer

Seruga, B., Zhang, H., Bernstein, L. J., & Tannock, I. F. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2507 · Cited by 652 · see citing works

Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy

Starobova, H., & Vetter, I. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00174 · Cited by 656 · see citing works

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

Reck, M., Bondarenko, I., Luft, A. V., Serwatowski, P., Barlési, F., Chacko, R. T., Sebastian, M., Lü, H., Cuillerot, J.-M., & Lynch, T. J. (2012) · Annals of Oncology · doi:10.1093/annonc/mds213 · Cited by 608 · see citing works

Role of Immunotherapy in Triple-Negative Breast Cancer

Keenan, T. E., & Tolaney, S. M. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.7554 · Cited by 608 · see citing works

CD4+ Lymphoid Tissue-Inducer Cells Promote Innate Immunity in the Gut

Sonnenberg, G. F., Monticelli, L. A., Elloso, M. M., Fouser, L. A., & Artis, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.12.009 · Cited by 573 · see citing works

BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

Bockorny, B., Semenisty, V., Macarulla, T. M., Borazanci, E. H., Wolpin, B. M., Stemmer, S. M., Golan, T., Geva, R., Borad, M. J., Pedersen, K. S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0880-x · Cited by 563 · see citing works

Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors

Gonçalves, B., Ferreira, C., Alves, C. T., Henriques, M., Azeredo, J., & Silva, S. (2016) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2015.1091805 · Cited by 669 · see citing works

The gut microbiota influences anticancer immunosurveillance and general health

Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0006-2 · Cited by 523 · see citing works

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

Peng, J., Hamanishi, J., Matsumura, N., Abiko, K., Murat, K., Baba, T., Yamaguchi, K., Horikawa, N., Hosoe, Y., Murphy, S. K., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3098 · Cited by 525 · see citing works

Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido

Balachandran, V. P., Cavnar, M. J., Zeng, S., Bamboat, Z. M., Ocuin, L. M., Obaid, H., Sorenson, E. C., Popow, R., Ariyan, C. E., Rossi, F., et al. (2011) · Nature Medicine · doi:10.1038/nm.2438 · Cited by 523 · see citing works

Human Solid Tumors Contain High Endothelial Venules: Association with T- and B-Lymphocyte Infiltration and Favorable Prognosis in Breast Cancer

Martinet, L., Garrido, I., Filleron, T., Guellec, S. L., Bellard, E., Fournié, J., Rochaix, P., & Girard, J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0431 · Cited by 523 · see citing works

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non–Small Cell Lung Cancer

Li, B., Cui, Y., Diehn, M., & Li, R. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1609 · Cited by 514 · see citing works

Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents

Buddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2047 · Cited by 508 · see citing works

Cancer Immunotherapy by Dendritic Cells

Melief, C. J. M. (2008) · Immunity · doi:10.1016/j.immuni.2008.08.004 · Cited by 505 · see citing works

Tumor Microenvironment‐Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade

Zhou, F., Feng, B., Yu, H., Wang, D., Wang, T., Ma, Y., Wang, S., & Li, Y. (2019) · Advanced Materials · doi:10.1002/adma.201805888 · Cited by 503 · see citing works

Molecular characteristics of immunogenic cancer cell death

Tesnière, A., Panaretakis, T., Kepp, O., Apétoh, L., Ghiringhelli, F., Zitvogel, L., & Kroemer, G. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402269 · Cited by 492 · see citing works

Myeloid-Derived Suppressor Cells

Parker, K. H., Beury, D. W., & Ostrand‐Rosenberg, S. (2015) · Advances in cancer research · doi:10.1016/bs.acr.2015.04.002 · Cited by 482 · see citing works

Leukocyte composition of human breast cancer

Ruffell, B., Au, A., Rugo, H. S., Esserman, L. J., Hwang, E. S., & Coussens, L. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104303108 · Cited by 481 · see citing works

Multiple Drug Resistance Mechanisms in Cancer

Baguley, B. C. (2010) · Molecular Biotechnology · doi:10.1007/s12033-010-9321-2 · Cited by 481 · see citing works

The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment

Kim, S. K., & Cho, S. W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.868695 · Cited by 473 · see citing works

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

Ramakrishnan, R., Assudani, D., Nagaraj, S., Hunter, T. B., Cho, H.-I., Antonia, S. J., Altiok, S., Celis, E., & Gabrilovich, D. I. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40269 · Cited by 460 · see citing works

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient

Jiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J. A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 449 · see citing works

Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment

Feng, B., Zhou, F., Hou, B., Wang, D., Wang, T., Fu, Y., Ma, Y., Yu, H., & Li, Y. (2018) · Advanced Materials · doi:10.1002/adma.201803001 · Cited by 450 · see citing works

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

Rizvi, N. A., Hellmann, M. D., Brahmer, J. R., Juergens, R. A., Borghaei, H., Gettinger, S. N., Chow, L. Q. M., Gerber, D. E., Laurie, S. A., Goldman, J. W., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.9861 · Cited by 446 · see citing works

Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities

Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.038 · Cited by 444 · see citing works

CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer

Liu, S., Lachapelle, J., Leung, S. C. Y., Gao, D., Foulkes, W. D., & Nielsen, T. O. (2012) · Breast Cancer Research · doi:10.1186/bcr3148 · Cited by 437 · see citing works

The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?

Savio, L. E. B., de Andrade Mello, P., da Silva, C. G., & Coutinho-Silva, R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00052 · Cited by 437 · see citing works

Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon–independent apoptosis in human melanoma cells

Besch, R., Poeck, H., Hohenauer, T., Senft, D., Häcker, G. A., Berking, C., Hornung, V., Endres, S., Ruzicka, T., Rothenfußer, S., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37155 · Cited by 429 · see citing works

Control of autophagy by oncogenes and tumor suppressor genes

Maiuri, M. C., Tasdemir, E., Criollo, A., Morselli, E., Vicencio, J. M., Carnuccio, R., & Kroemer, G. (2008) · Cell Death and Differentiation · doi:10.1038/cdd.2008.131 · Cited by 433 · see citing works

Amphiregulin Enhances Regulatory T Cell-Suppressive Function via the Epidermal Growth Factor Receptor

Zaiss, D. M. W., van Loosdregt, J., Gorlani, A., Bekker, C. P. J., Gröne, A., Sibilia, M. C., Henegouwen, P. M. P. V. B. E., Roovers, R. C., Coffer, P. J., & Sijts, A. J. A. M. (2013) · Immunity · doi:10.1016/j.immuni.2012.09.023 · Cited by 418 · see citing works

Cytokines as biomarkers of nanoparticle immunotoxicity

Elsabahy, M., & Wooley, K. L. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60064e · Cited by 408 · see citing works

Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity

Biase, S. D., Lee, C. D., Brandhorst, S., Manes, B., Buono, R., Cheng, C., Cacciottolo, M., Martín‐Montalvo, A., de Cabo, R., Wei, M., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.005 · Cited by 405 · see citing works

Chemotherapy: a double-edged sword in cancer treatment

Behranvand, N., Nasri, F., Emameh, R. Z., Khani, P., Hosseini, A., Garssen, J., & Falak, R. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03013-3 · Cited by 420 · see citing works

Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway

Zitvogel, L., Kepp, O., Senovilla, L., Menger, L., Chaput, N., & Kroemer, G. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2891 · Cited by 388 · see citing works

IKK/NF‐κB and STAT3 pathways: central signalling hubs in inflammation‐mediated tumour promotion and metastasis

Bollrath, J., & Greten, F. R. (2009) · EMBO Reports · doi:10.1038/embor.2009.243 · Cited by 381 · see citing works

Tumor Cell Death and ATP Release Prime Dendritic Cells and Efficient Anticancer Immunity

Aymeric, L., Apétoh, L., Ghiringhelli, F., Tesnière, A., Martins, I., Kroemer, G., Smyth, M. J., & Zitvogel, L. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3566 · Cited by 380 · see citing works

Anti- and pro-tumor functions of autophagy

Morselli, E., Galluzzi, L., Kepp, O., Vicencio, J. M., Criollo, A., Maiuri, M. C., & Kroemer, G. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.01.006 · Cited by 377 · see citing works

Mechanisms regulating T-cell infiltration and activity in solid tumors

Lanitis, E., Dangaj, D., Irving, M., & Coukos, G. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx238 · Cited by 369 · see citing works

Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis

Schiavoni, G., Sistigu, A., Valentini, M., Mattei, F., Sestili, P., Spadaro, F., Sanchez, M., Lorenzi, S., D'Urso, M. T., Belardelli, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2788 · Cited by 362 · see citing works

Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities

Kim, T. K., Vandsemb, E. N., Herbst, R. S., & Chen, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00493-5 · Cited by 359 · see citing works

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer

West, N. R., Milne, K., Truong, P. T., Macpherson, N. A., Nelson, B. H., & Watson, P. H. (2011) · Breast Cancer Research · doi:10.1186/bcr3072 · Cited by 355 · see citing works

Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment

Dijkgraaf, E. M., Heusinkveld, M., Tummers, B., Vogelpoel, L. T. C., Goedemans, R., Jha, V., Nortier, J. W. R., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3542 · Cited by 346 · see citing works

The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death

Panaretakis, T., Joza, N., Modjtahedi, N., Tesniere, A., Vitale, I., Durchschlag, M., Fimia, G. M., Kepp, O., Piacentini, M., Froehlich, K.-U., et al. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.67 · Cited by 344 · see citing works

Tumor organoids: Opportunities and challenges to guide precision medicine

Veninga, V., & Voest, E. E. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.020 · Cited by 339 · see citing works

Interaction of tumor-associated macrophages and cancer chemotherapy

Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596004 · Cited by 322 · see citing works

Interferon‐γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor‐associated macrophages

Duluc, D., Corvaisier, M., Blanchard, S., Catala, L., Descamps, P., Gamelin, E. C., Ponsoda, S., Delneste, Y., Hebbar, M., & Jeannin, P. (2009) · International Journal of Cancer · doi:10.1002/ijc.24401 · Cited by 328 · see citing works

DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity

Kitai, Y., Kawasaki, T., Sueyoshi, T., Kobiyama, K., Ishii, K., Zou, J., Akira, S., Matsuda, T., & Kawai, T. (2017) · Journal of Immunology · doi:10.4049/jimmunol.1601694 · Cited by 296 · see citing works

Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy

Wu, J., & Waxman, D. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.050 · Cited by 319 · see citing works

Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)

Boku, N., Ryu, M., Kato, K., Chung, H. C., Minashi, K., Lee, K.-W., Cho, H., Kang, W. K., Komatsu, Y., Tsuda, M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy540 · Cited by 314 · see citing works

Mitochondrial gateways to cancer

Galluzzi, L., Morselli, E., Kepp, O., Vitale, I., Rigoni, A., Vacchelli, E., Michaud, M., Zischka, H., Castedo, M., & Kroemer, G. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.08.002 · Cited by 296 · see citing works

Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy

Kepp, O., Galluzzi, L., Martins, I., Schlemmer, F., Adjemian, S., Michaud, M., Sukkurwala, A. Q., Menger, L., Zitvogel, L., & Kroemer, G. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9273-4 · Cited by 296 · see citing works

Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future

Sen, S., Won, M., Levine, M. S., Noh, Y., Sedgwick, A. C., Kim, J. S., Sessler, J. L., & Arambula, J. F. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00417d · Cited by 297 · see citing works

CD40 stimulation obviates innate sensors and drives T cell immunity in cancer

Byrne, K. T., & Vonderheide, R. H. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.05.058 · Cited by 282 · see citing works

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer

Nolan, E., Savas, P. S., Policheni, A. N., Darcy, P. K., Vaillant, F., Mintoff, C., Dushyanthen, S., Mansour, M., Pang, J., Fox, S. B., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal4922 · Cited by 293 · see citing works

Mechanisms of immune evasion in breast cancer

Bates, J. P., Derakhshandeh, R., Jones, L. P., & Webb, T. J. (2018) · BMC Cancer · doi:10.1186/s12885-018-4441-3 · Cited by 298 · see citing works

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages

Beatty, G. L., Winograd, R., Evans, R. A., Long, K. B., Luque, S. L., Lee, J. W., Clendenin, C. J., Gladney, W. L., Knoblock, D. M., Guirnalda, P. D., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.010 · Cited by 293 · see citing works

Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institution’s Experience with 52 Patients

Campana, L. G., D, S. M. M., Basso, M., Puccetti, O., Salvo, G. L. D., Chiarion‐Sileni, V., Vecchiato, A., Corti, L., Rossi, C. R., & Nitti, D. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-0204-8 · Cited by 290 · see citing works

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up

Adams, S., Diamond, J. R., Hamilton, E. P., Pohlmann, P. R., Tolaney, S. M., Chang, C., Zhang, W., Iizuka, K., Foster, P., Molinero, L. L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5152 · Cited by 290 · see citing works

The immune system and response to HER2-targeted treatment in breast cancer

Bianchini, G., & Gianni, L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70477-7 · Cited by 282 · see citing works

Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?

Apétoh, L., Ladoire, S., Coukos, G., & Ghiringhelli, F. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv209 · Cited by 281 · see citing works

Chemotherapy induces ATP release from tumor cells

Martins, I., Tesnière, A., Kepp, O., Michaud, M., Schlemmer, F., Senovilla, L., Séror, C., Métivier, D., Perfettini, J., Zitvogel, L., et al. (2009) · Cell Cycle · doi:10.4161/cc.8.22.10026 · Cited by 278 · see citing works

Autophagy regulates selective HMGB1 release in tumor cells that are destined to die

Thorburn, J., Horita, H., Redzic, J., Hansen, K., Frankel, A. E., & Thorburn, A. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.143 · Cited by 268 · see citing works

Modulation of Pulmonary Microbiota by Antibiotic or Probiotic Aerosol Therapy: A Strategy to Promote Immunosurveillance against Lung Metastases

Le Noci, V., Guglielmetti, S., Arioli, S., Camisaschi, C., Bianchi, F., Sommariva, M., Storti, C., Triulzi, T., Castelli, C., Balsari, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.090 · Cited by 270 · see citing works

Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment

Wang, Y., Lin, Y., Qiao, S., An, H., Ma, Y., Qiao, Z., Rajapaksha, R. P. Y. J., & Wang, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.034 · Cited by 267 · see citing works

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.67 · Cited by 931 · see citing works

Immune Effects of Conventional Cancer Therapeutics

Demaria, S., & Galluzzi, L. (2018) · Springer Publishing Company eBooks · doi:10.1891/9781617052736.0022

Activation of Immune-Mediated Tumor Cell Death by Chemotherapy

McCoy, M. J., Nowak, A. K., & Lake, R. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_14

Prerequisites for the Antitumor Vaccine-Like Effect of Chemotherapy and Radiotherapy

Hannani, D., Sistigu, A., Kepp, O., Galluzzi, L., Kroemer, G., & Zitvogel, L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325d4d · Cited by 86 · see citing works

Immunogenic effects of chemotherapy-induced tumor cell death

Wang, Y., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 316 · see citing works